Join Compass Therapeutics CEO, Thomas Schuetz, MD, PhD, at the Jefferies Global Healthcare Conference 2024 for a Fireside Chat on June 5 at 1 p.m. ET. ➡️ In-person: Track 2 - Plymouth, 6th Floor ➡️ Online: Register for the webcast at https://bit.ly/3KkjpbF #CMPX #Biotech #Biotechnology #JefferiesHealthcare
Compass Therapeutics Inc.’s Post
More Relevant Posts
-
Watch now: Prescient Therapeutics’ CEO & MD Steven Yatomi-Clarke provides an update on our strategy and upcoming milestones 💡 https://hubs.ly/Q02qRymS0 Focusing on PTX-100, Steven discusses how the upcoming PTX-100 Phase 2 trials places the company at a major value inflection point. #Biotech #PTX100 #CellTherapies #CancerTherapies
To view or add a comment, sign in
-
-
Exciting news from kashiv BioSciences! We announced the completion of Phase 3 patients recruitment for our first Mab molecule and have entered into a commercial partnership for the US, EU, and the rest of the world. Stay tuned for more updates on this groundbreaking development! #Biotechnology #Healthcare #Innovation
To view or add a comment, sign in
-
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/3tapYbd #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
To view or add a comment, sign in
-
GEN news has published their list of Top 25 Biotech Companies of 2024. According to it, ‘Biotechnology remains a profitable investment in the long term. Over the past five years, the market cap for the top 25 biotechnology companies soared nearly 78% from the combined $963.495 billion reported in GEN’s Top 25 Biotech Companies of 2019.’ . . . #Biotechnology #BiotechCompanies #CDM #ClinicalTrials #DigitalRevolution #Efficiency #Innovation #RealWorldData #ClinicalResearch #ClinicalTrials #healthcare #clinicaltrials #factsgram #DoYouKnow #mitconbiopharma #MITCON Priya Bande - Patil
To view or add a comment, sign in
-
Don't miss our Transforming Collaboration and Data Management webinar to learn how emerging biotechs like MOMA Therapeuticsuses Egnyte to facilitate collaboration, centralize content and preserve data integrity. Register for the webinar on 8/2 today! #lifesciences #biotech #biotechnology
To view or add a comment, sign in
-
Discover Formycon in the latest edition of the European Biotech Guide along with many other European Biotech companies that together represent the great success and multi-dimensionality of the European Biotech landscape. #TeamFormycon #Biotech #Biosimilars #Medicine #Europe #Biocom
To view or add a comment, sign in
-
-
GEN news has published their list of Top 25 Biotech Companies of 2024. According to it, ‘Biotechnology remains a profitable investment in the long term. Over the past five years, the market cap for the top 25 biotechnology companies soared nearly 78% from the combined $963.495 billion reported in GEN’s Top 25 Biotech Companies of 2019.’ . . . #Biotechnology #BiotechCompanies #CDM #ClinicalTrials #DigitalRevolution #Efficiency #Innovation #RealWorldData #ClinicalResearch #ClinicalTrials #healthcare #clinicaltrials #factsgram #DoYouKnow #mitconbiopharma #MITCON Priya Bande - Patil
To view or add a comment, sign in
-
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/46fDFEN #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
To view or add a comment, sign in
-
In the latest Bio Banter episode, Michael Margolis, RPh., and Daniel Parisotto, Ph.D., discuss the fascinating world of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics… Curious for more? Tune in today. https://bit.ly/3U43R1w #Therapeutics #Biotech #LetsTalkFuture #ThePowerofOppenheimerThinking
To view or add a comment, sign in
-
In the latest Bio Banter episode, Michael Margolis, R.Ph., and Daniel Parisotto, Ph.D., discuss the H1 2023 activity of private biotech markets. Do they see continued strength or decline? On the one hand, deal-making activities declined from the zeal of the pandemic highs, but things still look good compared to pre-pandemic metrics. Curious for more? Tune in today. https://bit.ly/48nY3Vo #Therapeutics #Biotech #Oppenheimer #LetsTalkFuture
To view or add a comment, sign in